Author/Authors :
Miyoshi، نويسنده , , Yasuo and Kurosumi، نويسنده , , Masafumi and Kurebayashi، نويسنده , , Junichi and Matsuura، نويسنده , , Nariaki and Takahashi، نويسنده , , Masato and Tokunaga، نويسنده , , Eriko and Egawa، نويسنده , , Chiyomi and Masuda، نويسنده , , Norikazu and Kim، نويسنده , , Seung Jin and Okishiro، نويسنده , , Masatsugu and Yanagisawa، نويسنده , , Tetsu and Ueda، نويسنده , , Satsuki and Taguchi، نويسنده , , Tetsuya and Tamaki، نويسنده , , Yasuhiro and Noguchi، نويسنده , , Shinzaburo، نويسنده ,
Abstract :
Epirubicin exerts its anti-tumor effect through binding to topoisomerase IIalpha (TOP2A) and inducing DNA double-strand breaks. BRCA1 is involved in the repair of these breaks. We investigated the relationship between TOP2A or BRCA1 immunohistochemical expression and pathological response in 108 primary breast cancers treated with epirubicin-based regimens. The pCR (pathological complete response) rate for TOP2A-positive (17%) was significantly (P < 0.005) higher than for TOP2A-negative (2%), while the pCR rate for BRCA1-negative (11%) was non-significantly higher than for BRCA1-positive (5%). The pCR rate of TOP2A-positive and BRCA1-negative (30%) was significantly higher than for TOP2A-negative and BRCA1-positive (3%; P < 0.05), or TOP2A-negative and BRCA1-negative (0%; P < 0.005). The TOP2A-positive and BRCA1-negative phenotype associates with a favorable response to epirubicin-based regimens.
Keywords :
breast cancer , BRCA1 , Pathological response , Epirubicin , Topoisomerase IIalpha
